Ligandal is a regenerative medicine, peptide and gene therapy technology company developing unique approaches for a variety of diseases. Our current pipeline is focused on developing antidotes and vaccines against COVID-19.
peptide antidotes to sars-cov-2 (covid-19)
https://www.biorxiv.org/content/10.1101/2020.08.06.238915v2
Have Ligandal Found a COVID-19 Treatment and SARS-CoV-2 Vaccine?
https://techround.co.uk/news/ligandal-covid-19-treatment-sars-cov-2-vaccine/
Peptide Scaffold Antidotes and Vaccines for SARS-CoV-2 and Biodefense
| peptide_scaffold_antidotes_and_vaccines_for_sars-cov-2_and_biodefense.pdf |
SYNTHETIC PEPTIDE ANTIDOTE-VACCINES
view our whitepaper:
Rapid Simulation and Design of Synthetic Peptide Mini-Scaffold Vaccines for Novel Coronavirus (SARS-CoV-2) and Pandemic Preparedness
PEPTIDE vaccine SCAFFOLDSOur peptide scaffolds will bolster the immune response to SARS-CoV-2.
|
ACE2 viral entry inhibitionThese scaffolds will also bind to the ACE2 receptor, preventing viral entry.
|
Immunoepitope mappingThe scaffolds contain multiple viral immunogenic domains.
|